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AbstrAct
Objectives To analyse the effect on therapeutic control 
and self-management skills of the implementation of self-
management programmes, including eHealth by e-learning 
versus group training.
setting Primary Care Thrombosis Service Center.
Participants Of the 247 oral anticoagulation therapy 
(OAT) patients, 63 started self-management by e-learning, 
74 self-management by group training and 110 received 
usual care.
Intervention and methods Parallel cohort design with 
two randomised self-management groups (e-learning 
and group training) and a group receiving usual care. The 
effect of implementation of self-management on time 
in therapeutic range (TTR) was analysed with multilevel 
linear regression modelling. Usage of a supporting eHealth 
platform and the impact on self-efficacy (Generalised Self-
Efficacy Scale (GSES)) and education level were analysed 
with linear regression analysis. After intervention, TTR was 
measured in three time periods of 6 months.
Main outcome measures (1) TTR, severe 
complications,(2) usage of an eHealth platform,(3) GSES, 
education level.
results Analysis showed no significant differences in 
TTR between the three time periods (p=0.520), the three 
groups (p=0.460) or the groups over time (p=0.263). 
Comparison of e-learning and group training showed no 
significant differences in TTR between the time periods 
(p=0.614), the groups (p=0.460) or the groups over time 
(p=0.263). No association was found between GSES and 
TTR (p=0.717) or education level and TTR (p=0.107). 
No significant difference was found between the self-
management groups in usage of the platform (0–6 
months p=0.571; 6–12 months p=0.866; 12–18 months 
p=0.260). The percentage of complications was low in all 
groups (3.2%; 1.4%; 0%).
conclusions No differences were found between OAT 
patients trained by e-learning or by a group course 
regarding therapeutic control (TTR) and usage of a 
supporting eHealth platform. The TTR was similar in self-
management and regular care patients. With adequate 
e-learning or group training, self-management seems safe 
and reliable for a selected proportion of motivated vitamin 
K antagonist patients.
trial registration number NTR3947.
IntrOductIOn
Venous thromboembolism (VTE) and atrial 
fibrillation (AF) are common causes of 
mortality and morbidity, with rising preva-
lence and medical costs.1–3 Oral anticoagula-
tion therapy (OAT) reduces thromboembolic 
events in AF, prosthetic heart valves, acute 
myocardial infarction and other conditions, 
and is an effective treatment for VTE.4–6 The 
major risks of OAT are bleeding complica-
tions, with a rate of major bleeding among 
long-term users of vitamin K antagonists 
(VKAs) of 1.5%–5.2% per year.7–9 There is a 
narrow therapeutic range for VKA, expressed 
as the international normalised ratio (INR) 
with an optimal intensity, related to a low 
rate of events, between 2.5 and 4.9.10 11 This 
is relevant, as patients have considerable diffi-
culty in maintaining adequate adherence to 
VKA regimens, with a significant effect on 
anticoagulation control.12 Structured moni-
toring and coaching of patients using VKA is 
essential. This may be carried out by special-
ised centres in primary care or in hospitals.13 
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Research
strengths and limitations of this study
 ► This study investigates the effect of different 
education and eHealth programmes in a situation as 
close to ‘real life’ as possible.
 ► The pragmatic study design will increase the 
applicability of the findings.
 ► The combination of clinical and usage data collection 
will give a deeper comprehension of the results.
 ► A potential limitation is that patients were free to 
volunteer, which might have caused bias in our 
study groups.
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Table 1 Overview of the study design: details of groups 1, 2 and 3
Saltro Thrombosis Service Centre
Self-management Usual care
Patients Group 1 Group 2 Group 3
#72 #72 #72
Instruction E-learning Group course Basic short training
Disease-specific knowledge
Self-testing skills









Alternatively, patients might choose to self-manage their 
VKA monitoring. In the case of VKA, self-management 
includes monitoring INR values by patients (self-mon-
itoring) and, as a possible next step, self-adjustment of 
the medication dosage (self-dosage). Nowadays, patients 
are usually supported by improved eHealth supported 
self-management programme14 with more freedom, 
improved quality of life and self-efficacy and less burden 
of specialised centres.15 16 Research shows a reduction 
of thromboembolic events and in all-cause mortality 
for patients with self-management17 due to the fact that 
patients have greater responsibility, increased awareness, 
commitment and interest in their condition.18
Adequate self-management is important for all patients 
with OAT to improve adherence to medication, irrespec-
tive of the type of anticoagulation medicine they use.19–21 
The basic principle of self-management is behavioural 
change, which is necessary to improve the quality of life 
of patients and the primary outcomes of their health 
and disease.22 Research on chronic diseases such as 
diabetes,23 chronic obstructive pulmonary disease24 and 
heart failure25 has shown that aspects such as self-efficacy 
(belief in one’s capabilities to organise and execute the 
course of action required to produce given attainments), 
educational level, socioeconomic status, age and sex are 
influencing factors in successful self-management and 
predictors in eHealth usage.26
As education is the basic approach in the development 
of self-management skills, the strategy used to implement 
educational support is expected to affect the individual 
level of self-management and, thereby, clinical outcomes. 
To test this hypothesis, we designed the PORTALS study. 
The aim of this study was to analyse the effect on anti-
coagulation control of an intervention consisting of an 
education programme in combination with the use of an 
online self-management portal. The general definition of 
self-management is the individual’s ability to manage the 
symptoms, treatment, physical and psychosocial conse-
quences and lifestyle changes inherent in living with 
a chronic condition27; in line with this definition, both 
self-monitoring and self-dosage of medication are consid-
ered important self-management skills in the PORTALS 
study (PORtal implementation within anTicoagulation 
care; AmpLification of Selfmanagement).
MethOds
study design
For the PORTALS study, we designed a quality improve-
ment intervention and compared strategies in an imple-
mentation study.28 Two methods were developed to train 
long-term VKA patients of the Saltro Thrombosis Service 
(outpatient anticoagulation clinic and laboratory) in 
self-management routine care. Using this design, we 
aimed to examine the influence of the training strategy 
on clinical outcomes and usage of the supporting eHealth 
platform. Full methodological details are reported else-
where29; Table 1 presents an overview of the study design.
A parallel cohort design was used to investigate deter-
minants of optimal implementation of self-management 
by comparing two different training methods. After inclu-
sion, participants were randomly divided into subgroups: 
one group was trained and educated by e-learning (group 
1) and the other group received face-to-face group training 
(group 2). Patients unable or unwilling to dose their medi-
cation were free to continue with only self-monitoring. 
Patients who did not wish to start with self-management 
were invited to participate in the non-self-management 
group, that is, a parallel cohort group receiving usual care 
(group 3). Group three provided valuable information 
about the patients who were unable/unwilling to use an 
online supported self-management programme.
Based on our parallel cohort design, comparison 
between e-learning and group training for self-manage-
ment (group 1 and 2) and non-self-management patients 
(group 3) is applicable, considering the specific condi-
tions in the choice of the statistics.
Participants
The present study focused on patients of the Saltro 
Thrombosis Service who voluntarily chose to start with 
self-management. The inclusion criteria for patients to 
start with self-management were a long-term indication 
for anticoagulants, internet access and stable INR values 
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Table 2 Training methods in group 1, 2 and 3
Group 1 Group 2 Group 3
General education (e-learning)   about 
anticoagulation+test
Self-testing device
Training (e-learning) self-testing+use of web portal
Three months of e-learning+self-testing
Group course with training self-testing+use of web 
portal
3 weeks practice at home
Group course about anticoagulation
3 months of training at home
Basic training
Self-testing device Self-testing device Venipuncture at home 
or in facilities
Control and quality check by nurse
Continuing self-management 
programme+control and quality check by nurse 
every 6 months
Control and quality check by nurse
Continuing self-management 
programme+control and quality check by nurse 
every 6 months
Written instructions by 
thrombosis doctor
(at least three INR values in succession must be within 
therapeutic range). Patients who met the criteria for 
self-management were approached for participation in 
the study. Because self-management (including eHealth) 
is already an option for patients of the Saltro Thrombosis 
Service, the group training was also open to patients who 
were not willing to participate in the study. The e-learning 
was reserved for participants of the present study, as this 
was a new implementation method. All patients provided 
written informed consent before participation in the 
study.
Patient involvement
Patients were neither involved in the design nor in 
defining research questions and outcome measures of 
the study; however, they were actively involved in the 
development of the self-management platform Porta-
vita. To maximise the involvement of patients, we did not 
randomise the intervention groups (self-management 
and usual care); we chose a recruitment design in which 
patients of the Thrombosis Service voluntarily chose to 
start with self-management. During the study, patients 
could give feedback on the intervention and on the 
self-management platform; their satisfaction was continu-
ously monitored. Feedback from patients made it possible 
to optimise their care. All patients will be informed about 
the results of this study.
recruitment of patients and non-participation
Patients of the Saltro Thrombosis Service who received 
regular care without a self-management programme were 
eligible for recruitment. In 2013, 8950 patients received 
usual care from the Saltro Thrombosis Service of which 
85% had a long-term indication. From June 2013 onward, 
a random selection of 1632 patients was approached for 
participation in the present study using three methods, 
(1) information and invitation by letter, (2) personal 
invitation by specialised nurses and (3) invitation by tele-
phone. Patients who did not wish to start with self-man-
agement were invited to participate in a parallel cohort 
group receiving usual care (group 3), thereby providing 
valuable information about non-participants. Base-
line characteristics of all regular patients of the Saltro 
Thrombosis Service also provided valuable information 
about non-participants.
Intervention
The intervention in groups 1 and 2 consisted of a training 
programme in combination with the use of an online 
self-management portal called Portavita. In group 1, 
patients used an e-learning that was specifically designed 
for the PORTALS study (see online multimedia supple-
mentary appendix 1).
Table 2 summarises the programme in all groups: 
the e-learning modules in group 1, the group training 
modules in group 2 and the basic training in group 3. 
In group 1, the training was provided by e-learning that 
started with a personal login procedure and an online 
instruction; the interim control and quality checks were 
carried out by specialised nurses of the Thrombosis 
Service. The group course in group two was carried out 
by specialised and expert healthcare professionals. Both 
training methods had the same content but were offered 
in a completely different manner.
In the PORTALS study, the online self-management 
portal used is called Portavita (see online multimedia 
supplementary appendix 2). This application combines 
a patient portal and a healthcare provider portal. The 
healthcare portal leaves space for the OAT protocol, medi-
cation records and information about complications. The 
Portavita anticoagulation self-management patient portal 
has become widely accepted; it provides patients with a 
diary tool for self-monitoring and self-dosage, education; 
it also allows personal notes and healthcare professionals 
can send advice and notes to the patient. It implies that 
the patient analyses a drop of blood using a home INR 
monitor. The patient can access the web-based patient 
portal to enter the INR and specific information for the 
health professional (intervention, bleeding, change in 
medication, vacation, etc). Clinically validated inbuilt 
algorithms provide advice regarding the next dose and 
test interval. The only things needed are an internet 
connection and a device like a personal computer, tablet 
or smartphone. When logging on (username +password) 
for the first time to Portavita, every user was directed to 
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the homepage. From there, users could access all func-
tionalities of the portal. The logon procedure of this 
portal is based on Dutch security legislation and guide-
lines (the Dutch Personal Data Protection Act).
data collection
INR values, thromboembolic events, bleedings, medi-
cation and indication were monitored and registered 
continuously by patients in the portal and by profes-
sionals of the Saltro Thrombosis Service. We measured 
the INR, complications and medication during a period 
of 6 months before and 18 months after starting the inter-
vention (ie, 24 months in total). The data collection also 
consisted of questionnaires (at baseline and after each 
3×6-month period) to measure the determinants and 
outcomes. Patients of group 1 and 2 received these ques-
tionnaires by email, and patients in group 3 by email or by 
post. In addition, the number of self-tests and use of the 
portal were continuously registered in the portal. Data 
on the total population of the Saltro Thrombosis Service 
were also collected.
Outcome measures and determinants
The primary outcome of this study was therapeutic 
control expressed as the INR control over time and severe 
complications (bleedings and thromboembolic events). 
To summarise the INR control over time, the percentage 
of time in therapeutic range (TTR) of INR was used, 
calculated with the Rosendaal method.30 TTR values 
were calculated for two INR ranges (INR 2–3 and INR 
2–3.5) because different calculations are used in Dutch 
and in international guidelines. TTR was measured at 
four moments: at 6 months before intervention and at 
3×6-month periods (total of 18 months) after starting the 
intervention. Serious complications were defined as those 
needing treatment or medical evaluation. An indepen-
dent thrombosis specialist was responsible for classifying 
serious complications at the end of the trial. The total 
follow-up period for all these measures was 24 months.
Furthermore, the self-management skills of partic-
ipants were evaluated. Self-management skills were 
defined as usage of the self-management platform, 
reflected as the amount of login sessions. Self-mon-
itoring and self-dosage are registered within the 
same login session. The usage counts were analysed. 
The determinants were self-efficacy and sociodemo-
graphic characteristics. Self-efficacy was measured 
at baseline using the Generalised Self-Efficacy Scale 
(GSES), with items scored on a four-point scale with a 
higher score reflecting higher self-efficacy.31 Sociode-
mographic characteristics were assessed by an online 
questionnaire addressing the following character-
istics: age, gender, education level, marital status, 
working status (labour) and quality of life (QoL), 
which was assessed using the EuroQol-5D (EQ-5D) 
and displayed at baseline. The EQ-5D is a five-item 
questionnaire with a higher score reflecting a higher 
QoL.
sample size and statistical methods
To detect a relevant effect of the new implementation 
strategy of e-learning or group training (>5%)32 at a 
power 80% and α=0.05, we calculated that a sample 
size of 63 patients was required per group. Considering 
a 15% dropout, 72 (63/0.85) patients were needed 
per study group. Baseline characteristics between the 
three groups were explored using χ2 tests and Krus-
kal-Wallis tests.
To investigate the effect of the different implemen-
tation methods of training versus the parallel cohort 
group on TTR, multilevel linear regression modelling 
(mixed models) was used. First, TTR outcomes were 
compared between the three groups. A second (mixed 
models) analysis was used to compare the differ-
ence in effect between e-learning and group training 
(group 1 vs group 2) on TTR. The variable TTR was 
included as outcome in the model. The periods of 
TTR measurements (time), the group and the inter-
action term (time×group) were included as predictors.
Both analyses were adjusted for age and gender.
To examine the impact of GSES and education on 
the effect of the different implementation methods, 
multiple linear regression analyses were performed with 
TTR at time point 3 as outcome and GSES and educa-
tion as predictors. Analyses were adjusted for age and 
gender.
A linear regression analysis was used to analyse usage 
(mean number of login sessions) of the portal Portavita 
in groups 1 and 2.
results
A total of 1632 VKA patients of the Saltro Throm-
bosis Service were invited to participate, of which 56% 
(n=915) declined (figure 1). Patients were invited in 
three different ways: by letter (n=475), by personal 
invitation during a visit to the Thrombosis Service 
(n=692) and by telephone (n=465).  717 patients were 
interested in participation in the study; 247 patients 
eventually signed an informed consent. During the 
process of inviting patients for the PORTALS study, 
patients were asked about their reasons for not partic-
ipating: the main reasons were not having a computer 
or internet, no digital skills, the effort of participating 
in a trial and their high level of satisfaction with usual 
care.
Participants were included in the study only after 
providing written informed consent but, because 
some patients failed to do this, 247 participants 
were finally included. Of these, 110 continued to 
receive regular care (group 3) and 137 patients 
were randomly divided into group 1 and 2 using a 
computer program. After randomisation, 63 patients 
were included in group 1 (e-learning) and 74 in 
group 2 (group training). Figure 1 summarises the 
recruitment process, including the reasons for loss to 
follow-up.
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Figure 1 Flowchart of the PORTALS study.
Table 3 Clinical characteristics of the population of the 
Saltro Thrombosis Service
Total patients, N 11 132
Male, N (%) 6009 (54.0)
Self-management, N (%) 1986 (17.8)
Male self-management, N (%) 1260 (63.4)
Medication, N (%)
  Acenocoumarol 8360 (75.1)
  Phenprocoumon 2761 (24.8)
  Warfarin 11 (0.1)
Indications, N (%)
  Atrial fibrillation 7430 (66.8)
  Venous thromboembolism 1673 (15.0)
  Artificial valve 720 (6.5)
  Other 1309 (11.8)
Severe complications, N (%)
  Major bleedings 219 (2.0)
  Thromboembolism 85 (0.8)
characteristics of the total population of the thrombosis 
service
The characteristics of all VKA patients of the Saltro 
Thrombosis Service in 2015 are shown in table 3.
baseline characteristics of study participants
Table 4 presents the baseline characteristics of the partic-
ipants: median age was 66.9 years, and median TTR was 
54.7 (for INR range 2–3) and 79.1 (for INR range 2–3.5). 
Of these patients, 66% had an indication of AF and 77.3% 
used acenocoumarol as oral anticoagulation medication. 
No significant differences were found between the three 
groups for gender (χ22=0.38, p=0.826), TTR (χ
2
2=3.68, 
p=0.159), indication (χ22=8.33, p=0.215) and marital 
status (χ22=7.47, p=0.280). The three groups differed 
significantly in age (χ22=19.96, p=0.000), baseline GSES 
(χ22=15.08, p=0.001) and EQ-5D (χ
2
2=6.66, p=0.036), 
use of medication (χ22=15.23, p=0.004), education level 




therapeutic control before and after intervention
Figure 2A shows the TTR values using the INR 2-3 in the 
three groups, 6 months before the intervention and in 
the 3x6-month periods after the intervention; the TTR 
values using the INR 2-3.5 are presented in figure 2B 
(see online supplementary appendix 3).
Analysis of the three groups showed no significant 
difference in TTR values over time (F3,631=0.755, p=0.520), 
between the groups (F2,211=0.924, p=0.398) or between 
the groups over time (F6,631=1.009, p=0.418).
Analysis of the two self-management groups showed no 
significant differences in TTR values between the four 
time periods (F3,378 =0.602, p=0.614). Also, no significant 
differences in TTR were found between group 1 and 2 
(F3,378 =0.548, p=0.460) or between these two groups over 
time (F3,378 =1.335, p=0.263).
The sensitivity analyses showed that using an INR of 
2-3.5, instead of 2-3, had no marked effect on the results, 
although a significant time effect was found. Results are 
presented in figure 2B in Appendix 3.
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Table 4 Baseline characteristics of patients with VKA therapy in the PORTALS study
Group 1 Group 2 Group 3 p Value Total
N 63 74 110
Age in years* (IQR) 65.0a (56.2–67.7) 65.8a (56.4–70.4) 69.6b (64.0–74.9) 0.00† 66.9 (59.5–72.7)
Males, N (%) 47 (74.6) 52 (70.3) 81 (73.6) 0.826 180 (72.9)
TTR INR range 2-3 (%)* (IQR) 50.2 (39.1–67.1) 52.9 (39.0–68.6) 57.4 (40.1–75.1) 0.159 54.7 (39.8–70.7)
TTR INR range 2-3.5 (%)* (IQR) 76.3 (67.0–86.0) 77.1 (64.1–85.3) 85.6 (72.0–93.5) 0.159 79.1 (68.2–88.8)
GSES* (IQR) 3.5a (3.1–3.8) 3.3a,b (3.0–3.7) 3.1b (2.9–3.5) 0.001† 3.3 (3.0–3.7)
EQ-5D* (IQR) 1.0a (0.81–1.0) 0.84a,b (0.78–1.0) 0.84b (0.78–1.0) 0.036† 0.84 (0.81–1.0)
Indication, N (%)
  AF 42 (66.7) 44 (59.5) 77 (70.0) 0.215 163 (66)
  Venous thromboembolism 13 (20.6) 18 (24.3) 11 (10.0) 42 (17)
  Artificial valve 2 (3.2) 3 (4.1) 4 (3.6) 9 (3.6)
  Other 6 (9.5) 9 (12.2) 18 (16.4) 33 (13.4)
Medication, N (%)
  Acenocoumarol 51 (81)a 64 (86.5)a 76 (69.1)b 0.004† 191 (77.3)
  Phenprocoumon 10 (15.9)a 10 (13.5)a 34 (30.9)b 54 (21.9)
  Warfarin 2 (3.2)a 0 (0)a 0 (0)a 2 (0.8)
Education level, N (%)
  Low 7 (12.1)a 13 (19.1)a 33 (35.9)b 0.00† 53 (24.3)
  Medium 24 (41.4)a 32 (47.1)a 46 (50.0)a 102 (46.8)
  High 27 (46.6)a 23 (33.8)b 13 (14.1)c 63 (28.9)
Marital status, N (%)
  Married 49 (84.5) 50 (73.5) 73 (79.3) 0.280 172 (78.9)
  Widow 1 (1.7) 6 (8.8) 4 (4.3) 11 (5.0)
  Divorced 1 (1.7) 6 (8.8) 4 (4.3) 11 (5.0)
  Single 7 (12.1) 6 (8.8) 11 (12.0) 24 (11.0)
Labour, N (%)
  No paid work 28 (48.3)a 29 (42.6)a 39 (42.4)a 0.043† 96 (44.0)
  Paid work 19 (32.8)a 20 (29.4)a 14 (15.2)b 53 (24.3)
  Household 8 (13.8)a 11 (16.2)a 23 (25.0)a 42 (19.3)
  Incapacitated 3 (5.2)a 8 (11.8)a 16 (17.4)a 27 (12.4)
Each superscript (a,b,c) letter denotes a subset of sample categories which do not differ significantly from each other at the 0.05 level.
N Missing questionnaires: GSES 29, EQ5D 32, indication 0, medication 0, education 29, marital status 29, labour 29.
*Values are medians and corresponding IQR.
†Between-group differences (p<0.05).
AF, atrial fibrillation; EQ-5D, EuroQol five dimensions questionnaire; INR, international normalised ratio; GSES, General Self-efficacy Scale; TTR, time 
in therapeutic range; VKA, vitamin K antagonist.
During the 18-month period after the intervention, 
across all three groups, a total of three severe complications 
occurred (3/247=1.2%): that is, two muscular bleedings 
in the e-learning group (2/63=3.2%) and one cerebrovas-
cular accident among patients receiving group training 
(1/74=1.4%); no complications occurred in the usual care 
group.
educational level and Gses
Educational level was not associated with the TTR in the 
last 6 months (F2,198=2.263, p=0.107); education level did 
not modify the effect of the different implementation 
methods on TTR (F4,198=1.659, p=0.161).
No association was found between the GSES and TTR 
in the last 6 months (F1,198=0.132, p=0.717); GSES did 
not modify the effect of the different implementations 
methods on TTR (F2,198=1.762, p=0.174).
usage of the platform
Figure 3 presents the usage by patients in groups 1 and 
2 (using the log files of the Portavita platform) during 
the 18 months after start of the intervention. Patients 
logged on to the platform to register their INR; some 
also used it to establish their medication dosage or 
to communicate with healthcare professionals of the 
Thrombosis Service. There was no significant differ-
ence between groups 1 and 2 in usage of the platform 
during the three time periods (0-6 months: mean 
20.75, SD 5.20, F1,109 =0.091, p=0.764; 6-12 months: 
mean 13.00, SD 7.0, F1,109=0.029, p=0.866; 12-18 
months: mean 12.5, SD 7.39, F1,109=1.28, p=0.260).
dIscussIOn
In the present study, no differences were found in therapeutic 
control and usage of the platform between anticoagulation 
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Figure 2 A Health status based on TTR (for INR range 2–3) for the three groups. INR, international normalised ratio; TTR, time 
in therapeutic.
self-management patients trained by e-learning and by group 
training. Moreover, the clinical results for self-management 
patients were similar to those of patients receiving regular 
care. Therefore, we conclude that, with adequate training 
through e-learning or group training, self-management 
is safe and reliable for a selected proportion of motivated 
patients receiving VKA. The PORTALS study provides valu-
able information on different implementation methods of 
OAT self-management, including eHealth.
strengths and limitations
This PORTALS study has several strengths. First, the study 
investigates the effect of different education programmes 
in a situation as close to ‘real life’ as possible, integrated 
in a self-management programme including eHealth, on 
clinical outcomes and self-management skills. The study 
also adds evidence to the existing body of knowledge on 
implementation of eHealth; this is important because 
local political/financial factors have a major impact on 
successful integration of eHealth in daily practice and 
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Figure 3 Usage of the platform in group 1 and group 2 after start of the intervention.
because self-management is important for patients who 
will use VKAs in the future.33
This study also has limitations. First, a randomised 
controlled trial (RCT) was not feasible in our setting of 
an implementation design in a real-life healthcare system 
with patients who have differing demands. Instead, an 
observational study was considered the best option for 
our context, that is, patients cannot be denied or forced 
to start with self-management. Furthermore, self-man-
agement skills imply behavioural changes. However, 
behavioural changes require time, whereas the study 
period was restricted to 18 months. This study also has 
limitations typically associated with eHealth trials. For 
example, as patients were free to volunteer, bias might 
have occurred in our study groups. Users were self-se-
lected and were, presumably, motivated to use the educa-
tion programme (including the web-based platform) 
as would be expected in a real-life setting. Of the 1632 
invited OAT patients, 247 patients (15%) were willing 
to participate and provided informed consent. However, 
only 137 patients (8.4% of invited patients) wanted to 
participate in the self-management groups and were 
randomised; other studies have a similar low recruit-
ment rate for self-management trials.34 This phenom-
enon might have affected the measurability of differences 
and might also reduce differences between the groups. 
The high number of participants lost to follow-up in our 
study (‘law of attrition’; the phenomenon of participants 
stopping usage) is a common finding in eHealth evalu-
ations and one of the fundamental and methodological 
challenges in the evaluation of eHealth apps.35 The loss 
to follow-up is high with a risk of biased results due to user 
bias; therefore, these results are only applicable for users 
of eHealth.
The total population of the Thrombosis Service showed 
a lower percentage of men than the participants of the 
present study, although the distribution of indications/
medication was similar. In the total population, the 
percentage of severe complications was low (bleedings 
2%, thromboembolism 0.8%); during our study period 
the percentage of complications was also low (group 
e-learning =3.2%; group training =1.4%; group usual care 
=0%), indicating a high quality of thrombosis care.
During the process of inviting patients for the PORTALS 
study, we asked their reasons for not participating (main 
reasons were: not having a computer/internet, no digital 
skills, the effort of participating and their high level of 
satisfaction with usual care). The group with usual care 
differed significantly from the self-management groups 
on several baseline characteristics: that is, patients in 
usual care were older, had a lower education level and 
fewer of them had paid work. Also, they had a lower GSES 
and EQ-5D and made less use of acenocoumarol. Patients 
in the total population of the Thrombosis Service and 
in the usual care group, might have different wishes and 
expectations towards care than patients that chose for a 
group.bmj.com on September 28, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Talboom-Kamp EPWA, et al. BMJ Open 2017;7:e017909. doi:10.1136/bmjopen-2017-017909
Open Access
self-management programme; that is, self-management 
programmes are suitable for patients that are highly moti-
vated and have skills for self-management tasks.
Finally, to measure a significant difference in thera-
peutic control, 72 patients were needed in each group. 
Although these numbers were not entirely met in group 1 
(e-learning), analysis of the groups should be sufficiently 
powered to detect relevant differences. In addition, the 
high number of INR data points collected before and 
after the intervention has a substantial impact on the 
strength of the design and the multilevel linear analysis.
Due to these limitations, caution is required when 
generalising our results to general practice. However, the 
practical applicability of our results for other specialised 
OAT centres is positive, that is, the study provides prac-
tical insight into successful implementation of self-man-
agement programme consisting of high-quality training 
and usage of a patient platform.
Interpretation of findings
No overall significant differences in therapeutic control 
were found between the three groups; also, there was no 
difference in therapeutic control between the group with 
e-learning and group training. Therapeutic INR control 
was good in all groups; in the last 6 months of the inter-
vention period, all groups spent around 58% of time 
within the narrow therapeutic range 2-3 and 83% of time 
within the therapeutic range 2-3.5; this indicates high 
quality and is comparable to other studies.34 36 Anticoag-
ulation control levels around 60% for TTR of INR range 
2-3 are considered safe.36–38 In studies conducted outside 
specialised care facilities in several different regions, 
TTR ranged from 40% to 70%.13 The national guidelines 
for the INR range changed during the last 6 months of 
our PORTALS study; this had a negative impact on the 
TTR during our last measurement period. Complication 
rates also compared favourably with international data; 
our overall adverse event rate was low compared to other 
studies.39–41
In comparison to literature, the baseline quality of OAT 
management in the present study can be considered high 
in all groups; therefore, further improvement through 
a self-management programme including education 
was difficult to achieve and the outcomes in the groups 
remained the same. Finally, both training methods were 
comparable on the effect of anticoagulation control; for 
patients and healthcare professionals this means that a 
good e-learning programme is a good alternative for 
labour-intensive group trainings. Based on our study, we 
recommend considering self-management programmes 
supported by e-learning as the preferred plan of action for 
self-management for anticoagulation patients. Further-
more, self-management with an e-learning component 
is suitable for motivated patients with sufficient digital 
skills; in our opinion, regular anticoagulation care needs 
to remain available for the rest of the population.
Self-efficacy and educational level of users had no impact 
on therapeutic control for the different implementation 
methods. The construct of perceived self-efficacy reflects 
an optimistic self-belief31; a correlation can be under-
stood based on the belief that one can perform a novel or 
difficult task or cope with adversity (indicating a higher 
self-efficacy). In the present study, self-efficacy was compa-
rable to that in a healthy Dutch population.42 43
The practical value of the Portavita portal is very high 
for patients because of the functionalities of self-mon-
itoring, self-dosage and digital advice from professional 
healthcare providers. Because patients use the self-man-
agement programme, regular visits to medical facilities 
are unnecessary. Patients can manage their anticoagu-
lation in their own time and in their own chosen place. 
Thus, using the self-management programme gives them 
(extra) freedom; this might be a strong motivating factor 
for using the programme. Also, the training programmes 
were sound and sustainable during the entire study 
period, probably stimulating patients to persevere with 
their self-management programme. Moreover, e-learning 
and group training led to the same usage and, there-
fore, the same self-management skills. Therefore, we 
conclude that our e-learning and group training provide 
a good start for OAT patients that voluntarily start with a 
self-management programme including eHealth.
Self-management programmes with eHealth technol-
ogies for chronic conditions can be used to enhance 
self-management and revise the Chronic Care Model; 
patients who actively participate in their care achieve 
valuable and sustained improvement in well-being.44 45 In 
many eHealth studies, use of a Personal Health Record 
or self-management platform can promote an informed/
activated patient and augment the Chronic Care Model 
for self-management support and productive interac-
tions; even though a direct dosage–effect relation (usually 
analysed in a classical RCT) is not common in eHealth.46 
Self-management programmes with good training and 
practical eHealth platforms have the potential to make 
chronic care personalised in a blended care model; every 
patient needs a different approach for optimal thera-
peutic control. Healthcare providers need to embrace 
a different role and release tight protocols.47 Individual 
patients have different expectations and wishes, which 
should be a topic of conversation with each patient. 
The general scientific basis for self-management applies 
perfectly to anticoagulation patients, which is confirmed 
in our study.
More studies are needed (preferably with larger sample 
groups, and including non-users) to gain more insight 
into the preferences of various patient groups, as well as 
the related costs.
The substantial workload generated by integrating 
a web-based platform in an OAT self-management 
programme emphasises the importance of piloting 
and assessing workforce implications for OAT manage-
ment centres. The present results provide additional 
insight into the organisational aspects of the implemen-
tation of education programmes into a self-manage-
ment programme with a platform, including the need 
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to educate and coach patients in the use of web-based 
platforms.
cOnclusIOn
Our main finding is that there were no differences in ther-
apeutic control and usage of a supporting eHealth plat-
form between anticoagulation self-management patients 
trained by e-learning and by group training. Moreover, we 
found that clinical results for self-management patients 
are comparable to those of patients receiving usual care. 
We conclude that with appropriate and sound training 
through e-learning or group training, self-management 
seems safe and reliable for a selected proportion of moti-
vated patients receiving oral anticoagulation treatment. 
The PORTALS study provides valuable information on 
different implementation methods of oral anticoagula-
tion self-management, including eHealth.
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